Mechanisms of lipotoxicity in the cardiovascular system

Current Hypertension Reports

Volumn 14, Issue 6, 2012, Pages 517-531

  Wende, Adam R ^a   Symons, J David ^b   Abel, E Dale ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Adiponectin; Autophagy; Cardiac function; Cardiac lipoprotection; Cardiovascular disease; Ceramide; Diabetes; Endothelial dysfunction; Epigenetics; Glucotoxicity; Heart; Hypertension; Inflammation; Insulin resistance; Lipotoxicity; MicroRNA; Mitochondria; Nitric oxide; Nutrient oversupply; Obesity; Pathways and mechanisms; Reactive oxygen species; Vascular dysfunction; Vasculature

Indexed keywords

APOLIPOPROTEIN E; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANYLATE CYCLASE; INSULIN RECEPTOR SUBSTRATE 2; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE C; PROTEIN P53; SOMATOMEDIN C RECEPTOR;

ARTICLE; BINDING AFFINITY; CARDIOVASCULAR SYSTEM; CATALYSIS; ENDOPLASMIC RETICULUM; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; EPIGENETICS; FATTY ACID TRANSPORT; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HETEROZYGOSITY; HOMEOSTASIS; HOMOZYGOSITY; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIPID TRANSPORT; LIPOTOXICITY; MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; VASCULARIZATION; VASODILATATION;

BLOOD VESSELS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; LIPID METABOLISM; MYOCYTES, CARDIAC; OBESITY;

EID: 84870542800     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-012-0307-2     Document Type: Article

References (121)

1. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006;113:1888-904.
2. Jiang ZY, Lin YW, Clemont A, et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest. 1999;104:447-57. This manuscript provided some of the first experimental data for pathway specific regulation downstream of vascular insulin resistance. Specifically, decreased activation of IRS-1 and IRS-2selectively reduces PI3K signaling without altering the MAPK pathway.
3. Rask-Madsen C, Li Q, Freund B, et al. Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. Cell Metab. 2010;11:379-89. Evidence is provided that loss of insulin signaling in endothelium increases atherosclerotic lesion formation in part via a mechanism mediated by impaired eNOS activation.
4. Maeno Y, Li Q, Park K, et al. Inhibition of insulin signaling in endothelial cells by protein kinase C-induced phosphorylation of p85 subunit of phosphatidylinositol 3-kinase (PI3K). J Biol Chem. 2012;287:4518-30. This study identified a molecular mechanisms by which activation of PKC inhibits IRS1-mediated PI3K activation of eNOS via phosphorylation of the p85 subunit of PI3K.
5. Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res. 2010;106:1319-31.
6. Tang Y, Li G. Chronic exposure to high fatty acids impedes receptor agonist-induced nitric oxide production and increments of cytosolic Ca2+ levels in endothelial cells. J Mol Endocrinol. 2011;47:315-26.
7. Kuboki K, Jiang ZY, Takahara N, et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: A specific vascular action of insulin. Circulation. 2000;101:676-81.
8. Naruse K, Rask-Madsen C, Takahara N, et al. Activation of vascular protein kinase C-beta inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance. Diabetes. 2006;55:691-8. This study provides the first detailed exploration of PKC-activation by obesity-induced insulin resistance and the inhibition of eNOS signaling in vascular tissue.
9. Abe H, Yamada N, Kamata K, et al. Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J Clin Invest. 1998;101:1784-8.
10. Kubota T, Kubota N, Kumagai H, et al. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab. 2011;13:294-307. In addition to further supporting a role of IRS2 in endothelial eNOS signaling, this landmark paper highlights the requirement of intact endothelial cell insulin signaling to regulate myocyte glucose homeostasis.
11. Wheatcroft SB, Shah AM, Li JM, et al. Preserved glucoregulation but attenuation of the vascular actions of insulin in mice heterozygous for knockout of the insulin receptor. Diabetes. 2004;53:2645-52. This study provides some of the first evidence that impaired insulin signaling may alter NO-mediated regulation of vascular function that may precede defects in insulin mediated muscle glucose utilization.
12. Duncan ER, Walker SJ, Ezzat VA, et al. Accelerated endothelial dysfunction in mild prediabetic insulin resistance: The early role of reactive oxygen species. Am J Physiol Endocrinol Metab. 2007;293:E1311-9.
13. Kahn MB, Yuldasheva NY, Cubbon RM, et al. Insulin resistance impairs circulating angiogenic progenitor cell function and delays endothelial regeneration. Diabetes. 2011;60:1295-303. This study identified an important role for insulin signaling to maintain vascular function by directly regulating cellular repair mechanisms through recruitment of angiogenic progenitor cells.
14. Okamoto H, Nakae J, Kitamura T, et al. Transgenic rescue of insulin receptor-deficient mice. J Clin Invest. 2004;114:214-23.
15. Symons JD, McMillin SL, Riehle C, et al. Contribution of insulin and Akt1 signaling to endothelial nitric oxide synthase in the regulation of endothelial function and blood pressure. Circ Res. 2009;104:1085-94. The data presented in this study, using both in vitro and in vivo models, found that HFD-induced vascular dysfunction resulted from impaired eNOS phosphorylation independent of significant changes in insulin-mediated activation of Akt, and suggested an important role for circulating fatty acids in impairing eNOS function.
16. Abbas A, Imrie H, Viswambharan H, et al. The insulin-like growth factor-1 receptor is a negative regulator of nitric oxide bioavailability and insulin sensitivity in the endothelium. Diabetes. 2011;60:2169-78. Findings in this report described the cross talk between insulin and IGF-1 receptors in regulating insulin sensitivity and NO action on vascular contractility.
17. Kim F, Pham M, Luttrell I, et al. Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ Res. 2007;100:1589-96. In an attempt to identify additional mechanisms of diet-induced vascular dysfunction, this study defined a new pathway for TLR4 in mediating saturated fatty acid induced impairment in endothelial NO signaling, inflammation, and insulin resistance.
18. Kim F, Pham M, Maloney E, et al. Vascular inflammation, insulin resistance, and reduced nitric oxide production precede the onset of peripheral insulin resistance. Arterioscler Thromb Vasc Biol. 2008;28:1982-8.
19. Molnar J, Yu S, Mzhavia N, et al. Diabetes induces endothelial dysfunction but does not increase neointimal formation in highfat diet fed C57BL/6J mice. Circ Res. 2005;96:1178-84.
20. Rizzo NO, Maloney E, Pham M, et al. Reduced NO-cGMP signaling contributes to vascular inflammation and insulin resistance induced by high-fat feeding. Arterioscler Thromb Vasc Biol. 2010;30:758-65.
21. Summers SA. Sphingolipids and insulin resistance: The five Ws. Curr Opin Lipidol. 2010;21:128-35.
22. Holland WL, Summers SA. Sphingolipids, insulin resistance, and metabolic disease: New insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev. 2008;29:381-402.
23. Zhang QJ, Holland WL, Wilson L, et al. Ceramide mediates vascular dysfunction in diet-induced obesity by PP2A-mediated dephosphorylation of the eNOS-Akt complex. Diabetes. 2012;61:1848-59. This study provided strong evidence linking ceramide that is generated by excess fatty acid delivery, to deactivation of the eNOS-Akt pathway in the endothelium. The molecular mechanism is a ceramide-dependent recruitment of the PP2A phosphatase to the eNOS/Akt signaling complex.
24. Wu Y, Song P, Xu J, et al. Activation of protein phosphatase 2A by palmitate inhibits AMP-activated protein kinase. J Biol Chem. 2007;282:9777-88.
25. Knopp RH, Retzlaff B, Walden C, et al. One-year effects of increasingly fat-restricted, carbohydrate-enriched diets on lipoprotein levels in free-living subjects. Proc Soc Exp Biol Med. 2000;225:191-9.
26. Schwartz EA, Reaven PD. Molecular and signaling mechanisms of atherosclerosis in insulin resistance. Endocrinol Metab Clin North Am. 2006;35:525-49.
27. Schwartz EA, Zhang WY, Karnik SK, et al. Nutrient modification of the innate immune response: A novel mechanism by which saturated fatty acids greatly amplify monocyte inflammation. Arterioscler Thromb Vasc Biol. 2010;30:802-8.
28. Kim F, Tysseling KA, Rice J, et al. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta. Arterioscler Thromb Vasc Biol. 2005;25:989-94. This study provides the first direct link between FFA-induced changes in NO signaling and IKKß to IRS-1 signaling in endothelial cells.
29. Liu K, Zhao W, Gao X, et al. Diosgenin ameliorates palmitateinduced endothelial dysfunction and insulin resistance via blocking IKKbeta and IRS-1 pathways. Atherosclerosis 2012, In press.
30. Maloney E, Sweet IR, Hockenbery DM, et al. Activation of NFkappaB by palmitate in endothelial cells: A key role for NADPHoxidase-derived superoxide in response to TLR4 activation. Arterioscler Thromb Vasc Biol. 2009;29:1370-5.
31. Miriyala S, Gongora Nieto MC, Mingone C, et al. Bone morphogenic protein-4 induces hypertension in mice: Role of noggin, vascular NADPH oxidases, and impaired vasorelaxation. Circulation. 2006;113:2818-25. Results presented in this manuscript are the first to define BMP4 as a novel regulator of endothelial function through a pathway that requires p47phox.
32. Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest. 2002;109:817-26.
33. Fonseca FV, Ravi K, Wiseman D, et al. Mass spectroscopy and molecular modeling predict endothelial nitric oxide synthase dimer collapse by hydrogen peroxide through zinc tetrathiolate metal-binding site disruption. DNA Cell Biol. 2010;29:149-60.
34. Wong SW, Kwon MJ, Choi AM, et al. Fatty acids modulate Tolllike receptor 4 activation through regulation of receptor dimerization and recruitment into lipid rafts in a reactive oxygen species-dependent manner. J Biol Chem. 2009;284:27384-92.
35. Erridge C, Samani NJ. Saturated fatty acids do not directly stimulate Toll-like receptor signaling. Arterioscler Thromb Vasc Biol. 2009;29:1944-9.
36. Holland WL, Bikman BT, Wang LP, et al. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J Clin Invest. 2011;121:1858-70. This study provided a direct link between inflammatory signaling and the generation of the toxic lipid intermediate ceramide, thereby providing a mechanism for linking inflammation, ceramide, and lipotoxic effects of saturated fatty acids.
37. Takabe K, Paugh SW, Milstien S, Spiegel S. "Inside-out" signaling of sphingosine-1-phosphate: Therapeutic targets. Pharmacol Rev. 2008;60:181-95.
38. Holland WL, Miller RA, Wang ZV, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med. 2011;17:55-63. Decreased adiponectin levels often accompany obesity. This study provides the first direct evidence that adiponectin may mediate some of its cardioprotective and beneficial metabolic effects by activating ceramidase activity.
39. Holland WL, Scherer PE. PAQRs. A counteracting force to ceramides? Mol Pharmacol. 2009;75:740-3.
40. Morales-Ruiz M, Lee MJ, Zollner S, et al. Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a Gi protein/phosphoinositide 3-kinase pathway in endothelial cells. J Biol Chem. 2001;276:19672-7. This study presents some of the first evidence implicating sphingosine mediated signaling in the regulation of PI3K and Akt signaling to eNOS.
41. Lee S, Zhang H, Chen J, et al. Adiponectin abates diabetesinduced endothelial dysfunction by suppressing oxidative stress, adhesion molecules, and inflammation in type 2 diabetic mice. Am J Physiol Heart Circ Physiol. 2012;303:H106-15.
42. Pangare M, Makino A. Mitochondrial function in vascular endothelial cell in diabetes. J Smooth Muscle Res. 2012;48:1-26. A thorough review of recent advances linking changes in mitochondrial ROS production, ion homeostasis, to changes in mitochondrial morphology and dynamics in regulating endothelial function.
43. Shenouda SM, Widlansky ME, Chen K, et al. Altered mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus. Circulation. 2011;124:444-53.
44. Makino A, Suarez J, Gawlowski T, et al. Regulation of mitochondrial morphology and function by O-GlcNAcylation in neonatal cardiac myocytes. Am J Physiol Regul Integr Comp Physiol. 2011;300:R1296-302.
45. Jheng HF, Tsai PJ, Guo SM, et al. Mitochondrial fission contributes to mitochondrial dysfunction and insulin resistance in skeletal muscle. Mol Cell Biol. 2012;32:309-19.
46. Corvisart des Marets JN. Of the degeneration of the muscular tissue of the heart into fat. In: An essay on the organic diseases and lesions of the heart and great vessels. Boston: Bradford & Read; 1812: 153-156.
47. Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol Rev. 2008;88:389-419. An exhaustive and comprehensive review of the mechanisms that lead to obesity-associated cardiac dysfunction in humans and in animal models of obesity.
48. Wende AR, Abel ED. Lipotoxicity in the heart. Biochim Biophys Acta. 2010;1801:311-9. This review provided an update into the molecular mechanisms by which lipid excess impairs cardiac function in humans and animal models.
49. Goldberg IJ, Trent CM, Schulze PC. Lipid metabolism and toxicity in the heart. Cell Metab. 2012;15:805-12. A recent review with a particular focus on the regulation of delivery of fatty acids to the heart and the role this plays in the development of lipotoxicity.
50. Stanley WC, Dabkowski ER, Ribeiro RF, O'Connell KA. Dietary fat and heart failure: Moving from lipotoxicity to lipoprotection. Circ Res. 2012;110:764-76. This review discusses some of the controversies surrounding lipotoxicity and reviews circumstances in which increased dietary intake of fat may result in cardioprotection.
51. O'Connor RD, Xu J, Ewald GA, et al. Intramyocardial triglyceride quantification by magnetic resonance spectroscopy: In vivo and ex vivo correlation in human subjects. Magn Reson Med. 2011;65:1234-8.
52. Labbé SM, Grenier-Larouche T, Croteau E, et al. Organ-specific dietary fatty acid uptake in humans using positron emission tomography coupled to computed tomography. Am J Physiol Endocrinol Metab. 2011;300:E445-53.
53. Niemann B, Chen Y, Teschner M, et al. Obesity induces signs of premature cardiac aging in younger patients: The role of mitochondria. J Am Coll Cardiol. 2011;57:577-85. A critical examination of cardiac myocytes from human patients identifying how changes in mitochondrial capacity and oxidative coupling are impaired with obesity, linking these defects in mitochondrial function to the increased susceptibility of cardiovascular complications in obese patients.
54. Baranowski M, Blachnio-Zabielska A, Hirnle T, et al. Myocardium of type 2 diabetic and obese patients is characterized by alterations in sphingolipid metabolic enzymes but not by accumulation of ceramide. J Lipid Res. 2010;51:74-80.
55. Marfella R, Di Filippo C, Portoghese M, et al. Myocardial lipid accumulation in patients with pressure-overloaded heart and metabolic syndrome. J Lipid Res. 2009;50:2314-23.
56. Winhofer Y, Krššák M, Jankovic D, et al. Short-term hyperinsulinemia and hyperglycemia increase myocardial lipid content in normal subjects. Diabetes. 2012;61:1210-6.
57. Bilet L, van de Weijer T, Hesselink MK, et al. Exercise-induced modulation of cardiac lipid content in healthy lean young men. Basic Res Cardiol. 2011;106:307-15.
58. Schrauwen-Hinderling VB, Hesselink MK, Meex R, et al. Improved ejection fraction after exercise training in obesity is accompanied by reduced cardiac lipid content. J Clin Endocrinol Metab. 2010;95:1932-8. This study exemplifies how lifestyle interventions can improve cardiac function in obese individuals that correlates with a reduction in cardiac lipid storage.
59. García-Rúa V, Otero MF, Lear PV, et al. Increased expression of fatty-acid and calcium metabolism genes in failing human heart. PLoS One 2012, 7:e37505.
60. Chokshi A, Drosatos K, Cheema FH, et al. Ventricular assist device implantation corrects myocardial lipotoxicity, reversesinsulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure. Circulation. 2012;125:2844-53.
61. Halbirk M, Norrelund H, Moller N, et al. Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function. Am J Physiol Heart Circ Physiol. 2010;299:H1220-5. This study presents a cautionary finding that pharmacological reduction of circulating FFA is not sufficient to improve cardiac contractile function in subjects with heart failure.
62. Turdi S, Kandadi MR, Zhao J, et al. Deficiency in AMP-activated protein kinase exaggerates high fat diet-induced cardiac hypertrophy and contractile dysfunction. J Mol Cell Cardiol. 2011;50:712-22.
63. Fang X, Palanivel R, Cresser J, et al. An APPL1-AMPK signaling axis mediates beneficial metabolic effects of adiponectin in the heart. Am J Physiol Endocrinol Metab. 2010;299:E721-9.
64. Li YJ, Wang PH, Chen C, et al. Improvement of mechanical heart function by trimetazidine in db/db mice. Acta Pharmacol Sin. 2010;31:560-9.
65. Tan SH, Shui G, Zhou J, et al. Induction of autophagy by palmitic acid via protein kinase c-mediated signaling pathway independent of mTOR (mammalian target of rapamycin). J Biol Chem. 2012;287:14364-76.
66. Khan MJ, Rizwan Alam M, Waldeck-Weiermair M, et al. Inhibition of autophagy rescues palmitic acid-induced necroptosis of endothelial cells. J Biol Chem. 2012;287:21110-20. This study provides one of the first examples directly linking autophagy to saturated fatty acid induced endothelial cell death.
67. Park TS, Hu Y, Noh HL, et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res. 2008;49:2101-12. This study described the requirement of ceramide synthesis via serine palmitoyltransferase in the development of cardiac lipotoxicity. Furthermore, it shows that inhibiting this pathway is a potential therapeutic avenue for restoring mitochondrial oxidative function, contractile function, and survival in a mouse model lipotoxic cardiomyopathy.
68. Ussher JR, Folmes CD, Keung W, et al. Inhibition of serine palmitoyl transferase 1 reduces cardiac ceramide levels and increases glycolysis rates following diet-induced insulin resistance. PLoS One. 2012;7:e37703.
69. Lee Y, Naseem RH, Duplomb L, et al. Hyperleptinemia prevents lipotoxic cardiomyopathy in acyl CoA synthase transgenic mice. Proc Natl Acad Sci U S A. 2004;101:13624-9. This study provided the first direct evidence that leptin signaling may protect against the development of lipotoxicity.
70. Sloan C, Tuinei J, Nemetz K, et al. Central leptin signaling is required to normalize myocardial fatty acid oxidation rates in caloric-restricted ob/ob mice. Diabetes. 2011;60:1424-34. This manuscript presents direct evidence that intact leptin signaling to the brain is required for systemic changes in obesity induced mitochondrial and cardiac dysfunction.
71. Keung W, Cadete VJ, Palaniyappan A, et al. Intracerebroventricular leptin administration differentially alters cardiac energy metabolism in mice fed a low-fat and high-fat diet. J Cardiovasc Pharmacol. 2011;57:103-13.
72. Rame JE, Barouch LA, Sack MN, et al. Caloric restriction in leptin deficiency does not correct myocardial steatosis: Failure to normalize PPARa/PGC1a and thermogenic glycerolipid/fatty acid cycling. Physiol Genomics. 2011;43:726-38.
73. Wölkart G, Schrammel A, Dörffel K, et al. Cardiac dysfunction in adipose triglyceride lipase deficiency: Treatment with a PPARa agonist. Br J Pharmacol. 2012;165:380-9.
74. Kienesberger PC, Pulinilkunnil T, Sung MM, et al. Myocardial ATGL overexpression decreases the reliance on fatty acid oxidation and protects against pressure overload-induced cardiac dysfunction. Mol Cell Biol. 2012;32:740-50.
75. Liu L, Yu S, Khan RS, et al. DGAT1 deficiency decreases PPAR expression and does not lead to lipotoxicity in cardiac and skeletal muscle. J Lipid Res. 2011;52:732-44.
76. Son NH, Yu S, Tuinei J, et al. PPAR?-induced cardiolipotoxicity in mice is ameliorated by PPARa deficiency despite increases in fatty acid oxidation. J Clin Invest. 2010;120:3443-54. This study underscored the complex interactions between members of the PPAR family of transcription factors in the regulation of fatty acid uptake, storage and oxidation the heart and showed that lipotoxicity can be ameliorated by simultaneously increasing fatty acid oxidation and triglyceride synthesis.
77. Mitra R, Nogee DP, Zechner JF, et al. The transcriptional coactivators, PGC-1a and beta, cooperate to maintain cardiac mitochondrial function during the early stages of insulin resistance. J Mol Cell Cardiol. 2012;52:701-10.
78. Nakamura H, Matoba S, Iwai-Kanai E, et al. p53 promotes cardiac dysfunction in diabetic mellitus caused by excessive mitochondrial respiration-mediated reactive oxygen species generation and lipid accumulation /clinical perspective. Circulation: Heart Failure. 2012;5:106-15.
79. Shimizu I, Yoshida Y, Katsuno T, et al. p53-induced adipose tissue inflammation is critically involved in the development of insulin resistance in heart failure. Cell Metab. 2012;15:51-64. Findings In This Study Revealed Important Cross Talk Between Adipose And Cardiac Tissue In Response To Pressure Overload. Specifically Regulation Of Lipolysis By P53 Enhances Inflammation And Leads To The Development Of Insulin Resistance.
80. Grueter CE Van Rooij E Johnson BA et al. A Cardiac Micro-RNA Governs Systemic Energy Homeostasis By Regulation Of MED13. Cell. 2012;149:671-83. This study revealed that a cardiac-restricted microRNA specifically regulates peripheral metabolic homeostasis. The specific cardiac mediator of this effect remains to be identified
81. Zhang L, Ussher JR, Oka T, et al. Cardiac diacylglycerol accumulation in high fat-fed mice is associated with impaired insulin-stimulated glucose oxidation. Cardiovasc Res. 2011;89:148-56.
82. Drosatos K, Bharadwaj KG, Lymperopoulos A, et al. Cardiomyocyte lipids impair beta-adrenergic receptor function via PKC activation. Am J Physiol Endocrinol Metab. 2011;300:E489-99.
83. Sharma V, Sharma A, Saran V, et al. beta-receptor antagonist treatment prevents activation of cell death signaling in the diabetic heart independent of its metabolic actions. Eur J Pharmacol. 2011;657:117-25.
84. Battiprolu PK, Hojayev B, Jiang N, et al. Metabolic stressinduced activation of FOXO1 triggers diabetic cardiomyopathy in mice. J Clin Invest. 2012;122:1109-18. The data presented in this manuscript directly links HFD induced transcriptional changes via the forkhead transcription factor FOXO1 to cardiac dysfunction and lipotoxic cardiomyopathy in a model of severe diet-induced obesity acting in part via decreased IRS-1 mediated Akt-signaling.
85. Wright JJ, Kim J, Buchanan J, et al. Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding. Cardiovasc Res. 2009;82:351-60. This study defines the time course of early changes in myocardial glucose and fatty acid utilization in the evolution of obesity-related cardiac dysfunction. Specifically, the authors identified an early defect in GLUT4-mediated glucose utilization that preceded any changes in cardiomyocyte insulin signaling.
86. Ferland-McCollough D, Fernandez-Twinn DS, Cannell IG, et al. Programming of adipose tissue miR-483-3p and GDF-3 expressionby maternal diet in type 2 diabetes. Cell Death Differ. 2012;19:1003-12.
87. Cazanave SC, Mott JL, Elmi NA, et al. A role for miR-296 in the regulation of lipoapoptosis by targeting PUMA. J Lipid Res. 2011;52:1517-25.
88. Greco S, Fasanaro P, Castelvecchio S, et al. MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes. 2012;61:1633-41. This study provides one of the first descriptions of altered regulation of microRNAs that relative to nondiabetics with heart failure, may represent a unique molecular signature in hearts of subjects with diabetes and heart failure.
89. Pulakat L, Aroor AR, Gul R, Sowers JR: Cardiac insulin resistance and microRNA modulators. Exp Diabetes Res 2012, In press.
90. Jordan SD, Kruger M, Willmes DM, et al. Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated Akt activation and impairs glucose metabolism. Nat Cell Biol. 2011;13:434-46. This study identified an essential role for changes in the microRNA (miRNA-143) in the regulation of insulin sensitivity and glucose homeostasis in the liver.
91. Sacco J, Adeli K. MicroRNAs: Emerging roles in lipid and lipoprotein metabolism. Curr Opin Lipidol. 2012;23:220-5.
92. Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by highdensity lipoproteins. Nat Cell Biol. 2011;13:423-33. This novel study provided direct evidence that high density lipoproteins (HDL), may serve as carriers of endogenous microRNAs, which in turn will regulate function in remote target organs.
93. Alfaradhi MZ, Ozanne SE. Developmental programming in response to maternal overnutrition. Front Genet. 2011;2:1-12.
94. Ng SF, Lin RCY, Laybutt DR, et al. Chronic high-fat diet in fathers programs ß-cell dysfunction in female rat offspring. Nature. 2010;467:963-6.
95. Dunn GA, Bale TL. Maternal high-fat diet effects on thirdgeneration female body size via the paternal lineage. Endocrinology. 2011;152:2228-36.
96. Carone BR, Fauquier L, Habib N, et al. Paternally induced transgenerational environmental reprogramming of metabolic gene expression in mammals. Cell. 2010;143:1084-96. This manuscript provides strong evidence that environmental factors, including dietary intake, have transgenerational effects on gene expression involved in metabolic function.
97. Rudyk O, Makra P, Jansen E, et al. Increased cardiovascular reactivity to acute stress and salt-loading in adult male offspring of fat fed non-obese rats. PLoS One. 2011;6:e25250.
98. Wilson CR, Tran MK, Salazar KL, et al. Western diet, but not high fat diet, causes derangements of fatty acid metabolism and contractile dysfunction in the heart of Wistar rats. Biochem J. 2007;406:457-67. This study was among the first to describe differential effects of increased dietary fat, versus the combination of increased dietary fat and carbohydrate in precipitating left ventricular dysfunction.
99. Ballal K, Wilson CR, Harmancey R, Taegtmeyer H. Obesogenic high fat western diet induces oxidative stress and apoptosis in rat heart. Mol Cell Biochem. 2010;344:221-30.
100. Cooksey RC, McClain DA. Increased hexosamine pathway flux and high fat feeding are not additive in inducing insulin resistance: Evidence for a shared pathway. Amino Acids. 2011;40:841-6.
101. Marsh SA, Powell PC, Dell'italia LJ, Chatham JC. Cardiac OGlcNAcylation blunts autophagic signaling in the diabetic heart. Life Sci 2012, In press.
102. Yan J, Young ME, Cui L, et al. Increased glucose uptake and oxidation in mouse hearts prevent high fatty acid oxidation but cause cardiac dysfunction in diet-induced obesity. Circulation. 2009;119:2818-28. This study provided direct evidence of the adverse consequences to the myocardium of forced increase in utilization of glucose and fatty acids.
103. Kolwicz SC, Olson DP, Marney LC, et al. Cardiac-specific deletion of acetyl CoA carboxylase 2 (ACC2) prevents metabolic remodeling during pressure-overload hypertrophy. Circ Res. 2012;111:728-38. This study describes a transgenic model with a lifelong increase in myocardial fatty acid oxidation that does not develop any evidence of lipotoxic compromise and exhibits preserved function when challenged with pressure overload, underscoring that complete fatty acid oxidation is not intrinsically damaging to the heart even when it is occurring at high levels.
104. Den Ruijter HM, Verkerk AO, Schumacher CA, et al. A diet rich in unsaturated fatty acids prevents progression toward heart failure in a rabbit model of pressure and volume overload. Circulation: Heart Failure. 2012;5:376-84.
105. Gordon GB. Saturated free fatty acid toxicity: II. Lipid accumulation, ultrastructural alterations, and toxicity in mammalian cells in culture. Exp Mol Pathol. 1977;27:262-76.
106. Greenberg AS, Coleman RA, Kraemer FB, et al. The role of lipid droplets in metabolic disease in rodents and humans. J Clin Invest. 2011;121:2102-10. This review presents a focused assessment of the role that lipid droplets play in regulating physiology and metabolism in the development of diabetic complications with a focus on liver, muscle, and adipocytes.
107. Wang H, Sreenevasan U, Hu H, et al. Perilipin 5, a lipid dropletassociated protein, provides physical and metabolic linkage to mitochondria. J Lipid Res. 2011;52:2159-68.
108. Kuramoto K, Okamura T, Yamaguchi T, et al. Perilipin 5, a lipid droplet-binding protein, protects heart from oxidative burden by sequestering fatty acid from excessive oxidation. J Biol Chem. 2012;287:23852-63.
109. Cheng Y, Li W, McElfresh TA, et al. Changes in myofilament proteins, but not Ca2+ regulation, are associated with a high-fat diet-induced improvement in contractile function in heart failure. Am J Physiol Heart Circ Physiol. 2011;301: H1438-46.
110. Berthiaume JM, Young ME, Chen X, et al. Normalizing the metabolic phenotype after myocardial infarction: Impact of subchronic high fat feeding. J Mol Cell Cardiol. 2012;53:125-33.
111. Chambers KT, Leone TC, Sambandam N, et al. Chronic inhibition of pyruvate dehydrogenase in heart triggers an adaptive metabolic response. J Biol Chem. 2011;286:11155-62.
112. Christopher BA, Huang HM, Berthiaume JM, et al. Myocardial insulin resistance induced by high fat feeding in heart failure is associated with preserved contractile function. Am J Physiol Heart Circ Physiol. 2010;299:H1917-27. The studies presented in this manuscript focus on the role that HFD-feeding may play in protecting against pathological insults by inducing insulin resistance in the cardiomyocyte.
113. Shimizu I, Minamino T, Toko H, et al. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J Clin Invest. 2010;120:1506-14. This Study Provides Direct Evidence That Pressure Overload And Myocyte Stretch Increases Insulin Signaling In The Heart And This Increased Insulin Signaling May Contribute To Adverse Left Ventricular Remodeling By Hyperactivating Akt. The Study Provides A Mechanism For Potential Beneficial Effects Of Myocardial Insulin Resistance.
114. This study provides direct evidence that pressure overload and myocyte stretch increases insulin signaling in the heart and this increased insulin signaling may contribute to adverse left ventricular remodeling by hyperactivating Akt. The study provides a mechanism for potential beneficial effects of myocardial insulin resistance.
115. Harmancey R, Lam TN, Lubrano GM, et al. Insulin resistance improves metabolic and contractile efficiency in stressed rat heart. FASEB J. 2012;26:3118-26. This report suggests that insulin resistance resulting from high sucrose feeding may be a mechanism that protected rat hearts from excess fuel delivery.
116. Bugger H, Riehle C, Jaishy B, et al. Genetic loss of insulin receptors worsens cardiac efficiency in diabetes. J Mol Cell Cardiol. 2012;52:1019-26.
117. Hu P, Zhang D, Swenson L, et al. Minimally invasive aortic banding in mice: Effects of altered cardiomyocyte insulin signaling during pressure overload. Am J Physiol Heart Circ Physiol. 2003;285:H1261-9.
118. Sena S, Hu P, Zhang D, et al. Impaired insulin signaling accelerates cardiac mitochondrial dysfunction after myocardial infarction. J Mol Cell Cardiol. 2009;46:910-8.
119. Matsui H, Yokoyama T, Sekiguchi K, et al. Stearoyl-CoA desaturase-1 (SCD1) augments saturated fatty acid-induced lipid accumulation and inhibits apoptosis in cardiac myocytes. PLoS One. 2012;7:e33283.
120. Ge F, Hu C, Hyodo E, et al. Cardiomyocyte triglyceride accumulation and reduced ventricular function in mice with obesity reflect increased long chain fatty acid uptake and de novo fatty acid synthesis. J Obes. 2012;2012:205648.
121. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011;123: e18-209.